Cargando…

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The IDH2 inhibitor enasidenib was recently approved for IDH2-mutated relapsed or refractory AML. We conducted a multi-center, phase I trial of maintenance enasidenib following alloge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fathi, Amir T., Kim, Haesook T., Soiffer, Robert J., Levis, Mark J., Li, Shuli, Kim, Annette S., Mims, Alice S., DeFilipp, Zachariah, El-Jawahri, Areej, McAfee, Steven L., Brunner, Andrew M., Narayan, Rupa, Knight, Laura W., Kelley, Devon, Bottoms, AJ S., Perry, Lindsey H., Wahl, Jonathan L., Brock, Jennifer, Breton, Elayne, Ho, Vincent T., Chen, Yi-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649991/ https://www.ncbi.nlm.nih.gov/pubmed/36150050 http://dx.doi.org/10.1182/bloodadvances.2022008632

Ejemplares similares

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
por: Kim, Yundeok, et al.
Publicado: (2020)

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
por: Wehrli, Marc, et al.
Publicado: (2022)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
por: Pollyea, Daniel A., et al.
Publicado: (2019)

Randomized Study of enterade(®) to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: De Filipp, Zachariah, et al.
Publicado: (2021)

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials
por: DeFilipp, Zachariah, et al.
Publicado: (2022)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
por: Annamaraju, Pavan, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation
por: Korell, Felix, et al.
Publicado: (2023)

Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms
por: McAfee, Darrian, et al.
Publicado: (2023)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

Arsenic toxicity manifesting as profuse watery diarrhea during induction therapy for acute promyelocytic leukemia
por: Ott, Ashley, et al.
Publicado: (2021)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy
por: Nardi, Valentina, et al.
Publicado: (2022)

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?
por: Abel, Gregory A., et al.
Publicado: (2020)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

Enterprise 2.0: how to manage social technologies to transform your organization
por: McAfee, Andrew
Publicado: (2009)

Full voice: the art and practice of vocal presence
por: McAfee, Barbara
Publicado: (2011)

Distress in a Pandemic: Association of the Coronavirus Disease-2019 Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation
por: Amonoo, Hermioni L., et al.
Publicado: (2021)

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
por: Galkin, Maria, et al.
Publicado: (2019)

Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application
por: Li, Shuang-long, et al.
Publicado: (2020)

Cases in construction supervision /
por: McAfee, R. Bruce
Publicado: (1977)

The Importance of Diagnosis and Treatment in Diseases of the Stomach
por: McAfee, Jno. C.
Publicado: (1902)

An Operation for Permanent and Quick Cure of Hemorrhoids, Almost Bloodless and Painless
por: McAfee, John C.
Publicado: (1903)

Spinal Navigation and Robotics Are More Accurate, More Precise, and More Minimally Invasive
por: McAfee, Paul C.
Publicado: (2022)

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
por: DeFilipp, Zachariah, et al.
Publicado: (2019)

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment
por: Li, Yan, et al.
Publicado: (2019)

UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics
por: Wang, Bo-wen, et al.
Publicado: (2021)

Smoking in Movies: A New Centers for Disease Control and Prevention Core Surveillance Indicator
por: McAfee, Tim, et al.
Publicado: (2012)

Empirically derived subgroups in rheumatoid arthritis: association with single-nucleotide polymorphisms on chromosome 6
por: Wilcox, Marsha A, et al.
Publicado: (2007)

Tobacco Use Patterns
por: McAfee, Timothy A., et al.
Publicado: (2012)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hgsok32lr6enfh6np04hr2h60r